CCG-203971, CAS 1443437-74-8

Product Description: CCG-203971 is a second-generation Rho/MRTF/SRF pathway inhibitor. CCG-203971 potently targets RhoA/C-activated SRE-luciferase (IC50 =6.4 μM). CCG-203971 inhibits PC-3 cell migration with an IC50 of 4.2 μM. Potential anti-metastasis Agent[1][2].

Applications: COVID-19-immunoregulation

Formula: C23H21ClN2O3

References: [1]Johnson LA, et al. Novel Rho/MRTF/SRF inhibitors block matrix-stiffness and TGF-β-induced fibrogenesis in human colonic myofibroblasts. Inflamm Bowel Dis. 2014 Jan;20(1):154-65./[2]Haak AJ, et al. Targeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury. J Pharmacol Exp Ther. 2014 Jun;349(3):480-6./[3]Bell JL, et al. Optimization of novel nipecotic bis(amide) inhibitors of the Rho/MKL1/SRF transcriptional pathway as potential anti-metastasis agents. Bioorg Med Chem Lett. 2013 Jul 1;23(13):3826-32.

CAS Number: 1443437-74-8

Molecular Weight: 408.88

Compound Purity: 98.0

Research Area: Inflammation/Immunology; Cancer

Solubility: DMSO : 250 mg/mL (ultrasonic)

Target: Ras

• Artikelnummer: MEXHY-108361-10.1
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-108361-10.1
• Verpackungseinheit: 10 mM/1 ml
• Mengeneinheit: STK